Steatohepatitis in obese individuals.
Nonalcoholic steatohepatitis (NASH), which is the most severe histological form of nonalcoholic fatty liver disease (NAFLD), is emerging as the most common clinically important form of liver disease in developed countries. Although its prevalence is 3% in the general population, this increases to 20-40% in obese patients. Since NASH is associated with obesity, prevalence has been predicted to increase along with the arsent epidemic of obesity and type II diabetes mellitus. The importance of this observation comes from the fact that NASH is a progressive fibrotic disease, in which cirrhosis and liver-related death occur in 25% and 10% in these patients respectively over a 10-year period. This is of particular concern given the increasing recognition of NASH in children. Treatment consists of treating obesity and its co-morbidities; diabetes and hyperlipidemia. Nascent studies suggest that a number of pharmacological therapies may be effective, but all remain unproven at present. Histological and laboratory improvement occurs with a 10% decrease in body weight. Bariatric surgery is indicated in selected patients.A greater understanding of the pathophysiological progression of NASH in obese patients must be obtained in order to develop more focused and improved therapy.
Youssef
Wael I
WI
Division of Gastroenterology, The Robert Schwartz Center for Metabolism and Nutrition at Metro-Health Medical Center, Case Western Reserve University, Cleveland, OH 44109, USA.
McCullough
Arthur J
AJ
D002908:Chronic Disease; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D018450:Disease Progression; D005234:Fatty Liver / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D009765:Obesity / Q000150:complications* / Q000453:epidemiology / Q000517:prevention & control; D015995:Prevalence; D012307:Risk Factors